HealthEquity, Inc. (NASDAQ:HQY) Stock Has Average Price Target of $112.20

Posted by Geri Gentry on Sep 27th, 2026

HealthEquity, Inc. (NASDAQ:HQY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $112.20.

Several equities analysts recently weighed in on the company. Weiss Ratings raised HealthEquity from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, September 16th. Wall Street Zen downgraded HealthEquity from a “buy” rating to a “hold” rating in a research report on Saturday, September 5th. Royal Bank Of Canada upped their target price on HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a report on Wednesday, June 3rd. BTIG Research restated a “buy” rating and issued a $115.00 price target on shares of HealthEquity in a research report on Friday, August 28th. Finally, Citizens Jmp lifted their price target on HealthEquity from $110.00 to $111.00 and gave the stock a “market outperform” rating in a research note on Monday, June 1st.

View Our Latest Analysis on HealthEquity

HealthEquity Stock Down 0.4%

HQY stock opened at $88.25 on Tuesday. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.47. The company’s 50-day moving average price is $99.06 and its 200 day moving average price is $90.30. HealthEquity has a 52 week low of $72.76 and a 52 week high of $107.62. The company has a market cap of $7.30 billion, a P/E ratio of 31.86, a P/E/G ratio of 1.39 and a beta of 0.22.

HealthEquity (NASDAQ:HQY – Get Free Report) last issued its earnings results on Thursday, August 27th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.05. The company had revenue of $350.73 million during the quarter, compared to analysts’ expectations of $349.22 million. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. HealthEquity’s revenue for the quarter was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. On average, research analysts expect that HealthEquity will post 3.93 earnings per share for the current fiscal year.

Insider Transactions at HealthEquity

In other news, Director Adrian T. Dillon sold 7,632 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total value of $798,383.52. Following the sale, the director directly owned 62,395 shares in the company, valued at $6,527,140.95. This represents a 10.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Fiore sold 2,470 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $95.00, for a total transaction of $234,650.00. Following the transaction, the executive vice president directly owned 56,643 shares of the company’s stock, valued at approximately $5,381,085. This trade represents a 4.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 12,456 shares of company stock valued at $1,256,664. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On HealthEquity

Institutional investors and hedge funds have recently bought and sold shares of the stock. Leonteq Securities AG increased its position in HealthEquity by 159.9% during the first quarter. Leonteq Securities AG now owns 382 shares of the company’s stock worth $32,000 after buying an additional 235 shares in the last quarter. Axiom Investment Management LLC acquired a new position in shares of HealthEquity in the first quarter worth $33,000. Silvant Capital Management LLC purchased a new stake in shares of HealthEquity in the second quarter valued at $35,000. Public Employees Retirement System of Ohio purchased a new stake in shares of HealthEquity in the second quarter valued at $39,000. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of HealthEquity by 2,476.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 438 shares of the company’s stock valued at $40,000 after acquiring an additional 421 shares during the last quarter. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

(Get Free Report)

HealthEquity, Inc provides technology-enabled services for consumer-directed benefits and healthcare savings accounts. The company helps employers, benefits advisors and individuals manage tax-advantaged accounts, including health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), commuter benefits and other employee benefit programs.

Its offerings include account administration, payment cards, reimbursement services, benefits communication, compliance support, healthcare spending tools and investment options for eligible HSA funds.